| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9157579 | Atherosclerosis | 2005 | 5 Pages |
Abstract
Twelve-week treatment with rosiglitazone improved EPC number and migratory activity of type 2 diabetic patients. The latter mechanism may contribute to the recently observed improvement of endothelial function by rosiglitazone in type 2 diabetes.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Frank Pistrosch, Kay Herbrig, Uta Oelschlaegel, Susannne Richter, Jens Passauer, Sabine Fischer, Peter Gross,